局部麻醉下经会阴自由手mpMRI融合靶向穿刺诊断前列腺癌:1014例多中心前瞻性研究
该多中心前瞻性研究纳入1014例mpMRI阳性患者,在局部麻醉下行经会阴靶向融合穿刺(含靶向和系统穿刺),临床显著前列腺癌(csPCa)检出率为39.4%。手术耐受良好(疼痛NRS 3.1±2.3),对勃起和排尿功能无影响,并发症少且无脓毒症;靶向穿刺联合系统穿刺可提高csPCa检出及与根治标本的一致性。
要点
- 局部麻醉下经会阴靶向融合穿刺可行、快速、耐受良好且安全,感染风险极低。
- csPCa检出率39.4%,疼痛NRS 3.1±2.3,勃起和排尿功能无显著改变。
核心结论
- 局部麻醉下经会阴mpMRI融合靶向穿刺可获得良好的csPCa检出,可行、快速、耐受良好且安全,感染风险可忽略。
- 补充系统穿刺可提高csPCa检出和与根治标本的ISUP分级一致性,但可能并非所有男性都需要。
研究设计与样本
- 多中心前瞻性研究,于2016年9月至2019年5月在两家三级转诊机构前瞻性筛查1327例mpMRI阳性患者,最终纳入1014例接受局部麻醉下经会阴靶向融合穿刺(靶向核心和系统核心)。
主要发现
- 1014例中csPCa(D1标准)诊断率为39.4%(n=400)。
- 手术耐受良好,疼痛NRS评分3.1±2.3;勃起功能(P=0.45)和排尿功能(P=0.58)无影响。
- 并发症低:Clavien-Dindo 1或2级8例,>2级0例;无穿刺后脓毒症记录。
- 穿刺与根治标本ISUP分级一致性:仅靶向核心k=0.40(95%CI 0.31-0.49),总体k=0.65(95%CI 0.57-0.72;P<0.05)。
关键数值与推荐
- csPCa定义D1:ISUP分级>1,或ISUP分级1但单核心前列腺癌占比>50%或>2个核心受累;D2:ISUP分级>1的前列腺癌。
- 疼痛评估采用数值评定量表(NRS);勃起功能采用国际勃起功能指数(IIEF);排尿功能采用国际前列腺症状评分(IPSS)。
- 并发症采用Clavien-Dindo分级。
临床怎么用
- 局部麻醉下经会阴靶向融合穿刺可作为mpMRI阳性患者前列腺癌诊断的可行选择,耐受性好且感染风险低。
- 靶向穿刺时可考虑补充系统穿刺以提高csPCa检出和分级一致性,但需权衡并非所有男性均需补充。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the outcomes of multiparametric magnetic resonance imaging (mpMRI) transperineal targeted fusion biopsy (TPFBx) under local anaesthesia. PATIENTS AND METHODS: We prospectively screened 1327 patients with a positive mpMRI undergoing TPFBx (targeted cores and systematic cores) under local anaesthesia, at two tertiary referral institutions, between September 2016 and May 2019, for inclusion in the present study. Primary outcomes were detection of clinically significant prostate cancer (csPCa) defined as (1) International Society of Urological Pathologists (ISUP) grade >1 or ISUP grade 1 with >50% involvement of prostate cancer (PCa) in a single core or in >2 cores (D1) and (2) ISUP grade >1 PCa (D2). Secondary outcomes were: assessment of peri-procedural pain (numerical rating scale [NRS]) and procedure timings; erectile (International Index of Erectile Function) and urinary (International Prostate Symptom Score) function changes; and complications. We also investigated the value of systematic sampling and concordance with radical prostatectomy (RP). RESULTS: A total of 1014 patients were included, of whom csPCa was diagnosed in 39.4% (n = 400). The procedure was tolerable (NRS pain score 3.1 ± 2.3), with no impact on erectile (P = 0.45) or urinary (P = 0.58) function, and a low rate of complications (Clavien-Dindo grades 1 or 2, n = 8; grade >2, n = 0). No post-biopsy sepsis was recorded. Twenty-two men (95% confidence interval [CI] 17-29) needed to undergo additional systematic biopsy to diagnose one csPCa missed by targeted biopsies (D1). ISUP grade concordance of biopsies with RP was as follows: k = 0.40 (95% CI 0.31-0.49) for targeted cores alone and k = 0.65 (95% CI 0.57-0.72; P < 0.05) overall. CONCLUSIONS: The use of TPFBx under local anaesthesia yielded good csPCa detection and was feasible, quick, well tolerated and safe. Infectious risk was negligible. Addition of systematic to targeted cores may not be needed in all men, although it improves csPCa detection and concordance with RP.
引用
- Marra G, Zhuang J, Beltrami M, et al. Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 cases. BJU Int. 2020. PMID: 32455504. doi:10.1111/bju.15121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。